Articles by Blood Cancers Today Staff Writers
Targeted next-generation sequencing of the full UBA1 locus was used to profile diagnostic and treatment-naïve samples.
Patients in the COMMANDS study were randomly assigned to luspatercept or epoetin alfa.
Of the patients included in the study, 67.6% were not transfusion dependent before initiating luspatercept.
Responses in hemoglobin, white blood cell, and platelet were 75%, 82%, and 74%, respectively, at 24 weeks.
Multivariable modeling showed a notable reduction in the risk of GVHD or relapse in the ATG group.
Hemoglobin and platelets are correlated with OS, while mutations in ASXL1, EZH2, IDH1/2, U2AF1, and SRSF2 are not.
Dr. Xia Jiang and colleagues collected AML cell lines to test the efficacy of venetoclax with NL-101.
Data differentiated the mechanisms of action of luspatercept from epoetin alfa in patients with transfusion-dependent LR-MDS.
Subjectivity of morphological assessment and overlapping pathological features of subtypes can hamper accurate MPN diagnosis.
Bomedemstat is an oral lysine-specific demethylase-1 (LSD1) inhibitor clinically active in patients with MPNs.
Researchers found that the proportion of cells in each CLL cluster was vastly different at relapse than it was at baseline.
Patients with CLL who eventually progress on BTK inhibitors highlights the need for new treatments.
Baseline mutational burden impacted response to erythropoiesis-stimulating agents in naïve patients with lower-risk MDS.
Patients with lower-risk MDS had better transfusion independence and erythroid response with luspatercept versus ESA agents.
Joshua Richter, MD, explained this finding and more results from the MyDRUG trial.
Rafael Renatino-Canevarolo, PhD, and colleagues explained just how the platform works.
Researchers studied patients with LR-MDS who had received an erythropoiesis-stimulating agent as frontline therapy.
Ruben Mesa, MD, discussed the results at the 65th ASH Annual Meeting and Exposition.
Researchers analyzed PV patients allocated to the ropeginterferon alfa-2b arm of the PROUD-PV/CONTINUATION-PV studies.
The use of combination therapies including XPO1 inhibitor selinexor is a potentially effective therapeutic strategy in MF.
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.